Bernhard Michael Polzer

Dr. Bernhard Michael Polzer


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
MWMelanie Werner-Klein
Melanie Werner-Klein
SSSebastian Scheitler
Sebastian Scheitler
MHMartin Hoffmann
Martin Hoffmann
IHIsabelle Hodak
Isabelle Hodak
KDKlaus Dietz
Klaus Dietz
CKChristoph A. Klein
Christoph A. Klein
Mouse models indicate that metastatic dissemination occurs extremely early; however, the timing in human cancers is unknown. We therefore determined the time point of metastatic seeding relative to tumour thickness and genomic alterations in melanoma. Here, we find that lymphatic dissemination occurs shortly after dermal invasion of the primary lesion at a median thickness of ~0.5 mm and that typical driver changes, includingBRAFmutation and gained or lost regions comprising genes likeMETorCDKNA2, are acquired within the lymph node at the time of colony formation. These changes define a colonisation signature that was linked to xenograft formation in immunodeficient mice and death from melanoma. Thus, melanoma cells leave primary tumours early and evolve at different sites in parallel. We propose a model of metastatic melanoma dormancy, evolution and colonisation that will inform direct monitoring of adjuvant therapy targets.

28 February 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
ALAnna Lorentzen
Anna Lorentzen
PBPaul F. Becker
Paul F. Becker
JKJan Kosla
Jan Kosla
MSMassimo Saini
Massimo Saini
KWKathrin Weidele
Kathrin Weidele
MHMathias Heikenwälder
Mathias Heikenwälder
Dynamic polarisation of tumour cells is essential for metastasis. While the role of polarisation during dedifferentiation and migration is well established, polarisation of metastasising tumour cells during phases of detachment has not been investigated. Here we identify and characterise a type of polarisation maintained by single cells in liquid phase termed single-cell (sc) polarity and investigate its role during metastasis. We demonstrate that sc polarity is an inherent feature of cells from different tumour entities that is observed in circulating tumour cells in patients. Functionally, we propose that the sc pole is directly involved in early attachment, thereby affecting adhesion, transmigration and metastasis. In vivo, the metastatic capacity of cell lines correlates with the extent of sc polarisation. By manipulating sc polarity regulators and by generic depolarisation, we show that sc polarity prior to migration affects transmigration and metastasis in vitro and in vivo.

5 October 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
MWMelanie Werner-Klein
Melanie Werner-Klein
AGAna Grujovic
Ana Grujovic
CIChristoph Irlbeck
Christoph Irlbeck
MOMilan Obradović
Milan Obradović
MHMartin Hoffmann
Martin Hoffmann
CKChristoph A. Klein
Christoph A. Klein
Although thousands of breast cancer cells disseminate and home to bone marrow until primary surgery, usually less than a handful will succeed in establishing manifest metastases months to years later. To identify signals that support survival or outgrowth in patients, we profile rare bone marrow-derived disseminated cancer cells (DCCs) long before manifestation of metastasis and identify IL6/PI3K-signaling as candidate pathway for DCC activation. Surprisingly, and similar to mammary epithelial cells, DCCs lack membranous IL6 receptor expression and mechanistic dissection reveals IL6 trans-signaling to regulate a stem-like state of mammary epithelial cells via gp130. Responsiveness to IL6 trans-signals is found to be niche-dependent as bone marrow stromal and endosteal cells down-regulate gp130 in premalignant mammary epithelial cells as opposed to vascular niche cells.PIK3CAactivation renders cells independent from IL6 trans-signaling. Consistent with a bottleneck function of microenvironmental DCC control, we findPIK3CAmutations highly associated with late-stage metastatic cells while being extremely rare in early DCCs. Our data suggest that the initial steps of metastasis formation are often not cancer cell-autonomous, but also depend on microenvironmental signals.

23 November 2015 in Expert Review of Molecular Diagnostics
Verified
Journal Article
Closed access
BABarbara Alberter
Barbara Alberter
CKChristoph A Klein
Christoph A Klein
BPBernhard Michael Polzer
Bernhard Michael Polzer
The generation of variant cancer cells is the major cause of acquired resistance against systemic therapies and consequently, of our inability to cure advanced cancer patients. Circulating tumor ce...

13 March 2023 in International Journal of Cancer
Verified
Journal Article
Open access
DKDaria Klusa
Daria Klusa
FLFabian Lohaus
Fabian Lohaus
AFAndre Franken
Andre Franken
MBMarian Baumbach
Marian Baumbach
MCMonica Cojoc
Monica Cojoc
CPClaudia Peitzsch
Claudia Peitzsch
Ablative radiotherapy is a highly efficient treatment modality for patients with metastatic prostate cancer (PCa). However, a subset of patients does not respond. Currently, this subgroup with bad prognosis cannot be identified before disease progression. We hypothesize that markers indicative of radioresistance, stemness and/or bone tropism may have a prognostic potential to identify patients profiting from metastases‐directed radiotherapy. Therefore, circulating tumor cells (CTCs) were analyzed in patients with metastatic PCa (n = 24) during radiotherapy with CellSearch, multicolor flow cytometry and imaging cytometry. Analysis of copy‐number alteration indicates a polyclonal CTC population that changes after radiotherapy. CTCs were found in 8 out of 24 patients (33.3%) and were associated with a shorter time to biochemical progression after radiotherapy. Whereas the total CTC count dropped after radiotherapy, a chemokine receptor CXCR4‐expressing subpopulation representing 28.6% of the total CTC population remained stable up to 3 months. At once, we observed higher chemokine CCL2 plasma concentrations and proinflammatory monocytes. Additional functional analyses demonstrated key roles of CXCR4 and CCL2 for cellular radiosensitivity, tumorigenicity and stem‐like potential in vitro and in vivo. Moreover, a high CXCR4 and CCL2 expression was found in bone metastasis biopsies of PCa patients. In summary, panCK+CXCR4+ CTCs may have a prognostic potential in patients with metastatic PCa treated with metastasis‐directed radiotherapy.

3 July 2019 in Cancers
Verified
Journal Article
Open access
PDF file
SCShukun Chen
Shukun Chen
GTGerlinde Tauber
Gerlinde Tauber
TLTanja Langsenlehner
Tanja Langsenlehner
LSLinda Maria Schmölzer
Linda Maria Schmölzer
MPMichaela Pötscher
Michaela Pötscher
Amin El-HeliebiAmin El-Heliebi
Amin El-Heliebi
High-risk non-metastatic prostate cancer (PCa) has the potential to progress into lethal disease. Treatment options are manifold but, given a lack of surrogate biomarkers, it remains unclear which treatment offers the best results. Several studies have reported circulating tumor cells (CTCs) to be a prognostic biomarker in metastatic PCa. However, few reports on CTCs in high-risk non-metastatic PCa are available. Herein, we evaluated CTC detection in high-risk non-metastatic PCa patients using the in vivo CellCollector CANCER01 (DC01) and CellSearch system. CTC counts were analyzed and compared before and after radiotherapy (two sampling time points) in 51 high-risk non-metastatic PCa patients and were further compared according to isolation technique; further, CTC counts were correlated to clinical features. Use of DC01 resulted in a significantly higher percentage of CTC-positive samples compared to CellSearch (33.7% vs. 18.6%; p = 0.024) and yielded significantly higher CTC numbers (range: 0–15 vs. 0–5; p = 0.006). Matched pair analysis of samples between two sampling time points showed no difference in CTC counts determined by both techniques. CTC counts were not correlated with clinicopathological features. In vivo enrichment using DC01 has the potential to detect CTC at a higher efficiency compared to CellSearch, suggesting that CTC is a suitable biomarker in high-risk non-metastatic PCa.